login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ESPERION THERAPEUTICS INC (ESPR) Stock News
USA
- NASDAQ:ESPR -
US29664W1053
-
Common Stock
2.82
USD
-0.08 (-2.76%)
Last: 11/17/2025, 8:00:02 PM
2.82
USD
0 (0%)
Pre-Market:
11/18/2025, 7:04:14 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ESPR Latest News, Press Relases and Analysis
All
Press Releases
12 days ago - By: Chartmill
Esperion Therapeutics Inc (NASDAQ:ESPR) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss
36 minutes ago - By: Esperion Therapeutics, Inc.
- Mentions:
HLS.CA
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
36 minutes ago - By: Esperion Therapeutics, Inc.
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
8 days ago - By: Esperion Therapeutics, Inc.
Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025
11 days ago - By: Zacks Investment Research
- Mentions:
RDY
ANIP
ARQT
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down
12 days ago - By: Esperion Therapeutics, Inc.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
12 days ago - By: Esperion Therapeutics, Inc.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
12 days ago - By: Benzinga
- Mentions:
AMSC
AOSL
VAC
ACHC
...
DoorDash Posts Downbeat Q3 Earnings, Joins elf Beauty, Duolingo, HubSpot And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
12 days ago - By: Benzinga
- Mentions:
STVN
PODD
AMRK
SOLV
...
Earnings Scheduled For November 6, 2025
12 days ago - By: Esperion Therapeutics, Inc.
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
12 days ago - By: Esperion Therapeutics, Inc.
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
14 days ago - By: Esperion Therapeutics, Inc.
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
14 days ago - By: Esperion Therapeutics, Inc.
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
15 days ago - By: Esperion Therapeutics, Inc.
Esperion to Participate in Jefferies Global Healthcare Conference - London
21 days ago - By: Esperion Therapeutics, Inc.
Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.
21 days ago - By: Esperion Therapeutics, Inc.
Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.
22 days ago - By: Esperion Therapeutics, Inc.
Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025
22 days ago - By: Esperion Therapeutics, Inc.
Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025
a month ago - By: Esperion Therapeutics, Inc.
Esperion to Report Third Quarter 2025 Financial Results on November 6
a month ago - By: Zacks Investment Research
- Mentions:
ANIP
EVO
CMMB
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
a month ago - By: Esperion Therapeutics, Inc.
Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis
a month ago - By: Esperion Therapeutics, Inc.
Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis
a month ago - By: Stocktwits
Why Is Esperion Therapeutics Stock Sinking Premarket Today?
a month ago - By: Esperion Therapeutics, Inc.
Esperion Announces Pricing of Public Offering of Common Stock
a month ago - By: Esperion Therapeutics, Inc.
Esperion Announces Pricing of Public Offering of Common Stock
a month ago - By: Esperion Therapeutics, Inc.
Esperion Announces Proposed Public Offering of Common Stock
a month ago - By: Esperion Therapeutics, Inc.
Esperion Announces Proposed Public Offering of Common Stock
2 months ago - By: Stocktwits
- Mentions:
IWMW
URTY
Esperion Shares Rally After Patent Litigation Settlement For Cholesterol Drugs
Please enable JavaScript to continue using this application.